Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US

Neutropenia is a common side-effect of chemotherapy and is a condition characterised by low levels of neutrophils, a type of white blood cell that fights infection. The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc, Aurobindo Pharma said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W3CuZIi
via IFTTT